1. Home
  2. CGON vs WMK Comparison

CGON vs WMK Comparison

Compare CGON & WMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • WMK
  • Stock Information
  • Founded
  • CGON 2010
  • WMK 1912
  • Country
  • CGON United States
  • WMK United States
  • Employees
  • CGON N/A
  • WMK N/A
  • Industry
  • CGON
  • WMK Food Chains
  • Sector
  • CGON
  • WMK Consumer Staples
  • Exchange
  • CGON NYSE
  • WMK Nasdaq
  • Market Cap
  • CGON 2.4B
  • WMK 2.0B
  • IPO Year
  • CGON 2024
  • WMK N/A
  • Fundamental
  • Price
  • CGON $28.45
  • WMK $72.13
  • Analyst Decision
  • CGON Strong Buy
  • WMK
  • Analyst Count
  • CGON 8
  • WMK 0
  • Target Price
  • CGON $63.88
  • WMK N/A
  • AVG Volume (30 Days)
  • CGON 819.4K
  • WMK 80.1K
  • Earning Date
  • CGON 02-02-2025
  • WMK 11-05-2024
  • Dividend Yield
  • CGON N/A
  • WMK 1.88%
  • EPS Growth
  • CGON N/A
  • WMK N/A
  • EPS
  • CGON N/A
  • WMK 3.56
  • Revenue
  • CGON $684,000.00
  • WMK $4,759,577,000.00
  • Revenue This Year
  • CGON $165.75
  • WMK N/A
  • Revenue Next Year
  • CGON $47.04
  • WMK N/A
  • P/E Ratio
  • CGON N/A
  • WMK $20.06
  • Revenue Growth
  • CGON 258.12
  • WMK N/A
  • 52 Week Low
  • CGON $25.77
  • WMK $58.87
  • 52 Week High
  • CGON $50.23
  • WMK $76.62
  • Technical
  • Relative Strength Index (RSI)
  • CGON 31.50
  • WMK 51.11
  • Support Level
  • CGON $27.58
  • WMK $70.67
  • Resistance Level
  • CGON $36.73
  • WMK $71.88
  • Average True Range (ATR)
  • CGON 2.01
  • WMK 1.36
  • MACD
  • CGON -0.52
  • WMK -0.23
  • Stochastic Oscillator
  • CGON 9.51
  • WMK 42.92

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About WMK Weis Markets Inc.

Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products consist of center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.

Share on Social Networks: